Claims for Patent: 9,144,609

Summary for Patent: 9,144,609

Title:	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Abstract:	An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. An embodiment of said liquid preparation does not include any preservative. Said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
Inventor(s):	Sawa; Shirou (Hyogo, JP), Fujita; Shuhei (Hyogo, JP), Baklayan; George A. (Huntington Beach, CA), Padilla; Angeliqueo E. (Aliso Viejo, CA)
Assignee:	SENJU PHARMACEUTICAL CO., LTD. (Osaka, JP)
Application Number:	14/269,692
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,144,609
Patent Claims:	1. A stable aqueous liquid preparation consisting essentially of: (a) a first component; (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; (c) boric acid; (d) sodium tetraborate; and (e) water; wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.05 w/v % to about 0.2 w/v %; the second component is tyloxapol and is present in said liquid preparation in an amount sufficient to stabilize said first component; and wherein said stable liquid preparation is formulated for ophthalmic administration. 2. The aqueous liquid preparation according to claim 1, wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt. 3. The aqueous liquid preparation according to claim 1, wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v %. 4. The aqueous liquid preparation according to claim 1, wherein the pH of the aqueous liquid preparation is from about 7 to about 7.5. 5. The stable aqueous liquid preparation of claim 1; wherein the stable aqueous liquid preparation consists of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) water; and (f) a pH adjuster; wherein said liquid preparation is formulated for ophthalmic administration, and wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.04 w/v% to about 0.1 w/v %, and wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v %. 6. A stable aqueous liquid preparation consisting essentially of: (a) a first component; (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; (c) boric acid; (d) sodium tetraborate; and (e) water; wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.04 w/v % to about 0.1 w/v %; the second component is tyloxapol; wherein said stable liquid preparation is formulated for ophthalmic administration; and wherein the stable aqueous liquid preparation is characterized in that at least about 89% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks. 7. The aqueous liquid preparation according to claim 6; wherein the stable aqueous liquid preparation is characterized in that greater than about 92% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks. 8. The aqueous liquid preparation according to claim 6; wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v %; and wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.04 w/v % to about 0.1 w/v %. 9. The aqueous liquid preparation according to claim 8, wherein the pH is from about 7 to about 7.5. 10. The stable aqueous liquid preparation of claim 6; wherein the stable aqueous liquid preparation consists of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) water; and (f) a pH adjuster; and wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 w/v % to about 0.08 w/v %, and the concentration of tyloxapol is about 0.02 w/v%. 11. A stable aqueous liquid preparation consisting essentially of: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; (c) boric acid; (d) sodium tetraborate; and (e) water; wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.04 w/v % to about 0.2 w/v %; the second component is tyloxapol; wherein said stable liquid preparation is formulated for ophthalmic administration; provided that the liquid preparation does not include mannitol. 12. The aqueous liquid preparation according to claim 11, wherein the aqueous liquid preparation further consists of sodium sulfite. 13. The aqueous liquid preparation according to claim 11, wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt. 14. The aqueous liquid preparation according to claim 11, wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v % and the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 to about 0.08 w/v %. 15. The aqueous liquid preparation according to claim 11, wherein the pH is from about 7 to about 7.5. 16. The stable aqueous liquid preparation of claim 11; wherein the stable aqueous liquid preparation consists of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) water; (f) disodium edetate; (g) sodium sulfite; and (h) a pH adjuster; wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.04 w/v% to about 0.1 w/v %, and the concentration of tyloxapol is from about 0.01 w/v% to about 0.05 w/v %. 17. The stable aqueous liquid preparation of claim 11; wherein the stable aqueous liquid preparation is characterized in that at least about 89% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks. 18. The stable aqueous liquid preparation of claim 11; wherein the stable aqueous liquid preparation is characterized in that at least about 92% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks. 19. The stable aqueous liquid preparation according to claim 18, wherein the concentration of tyloxapol is from about 0.02 w/v % to about 0.03 w/v %; and wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 w/v % to about 0.08 w/v %. 20. The aqueous liquid preparation according to claim 19, wherein the pH of the aqueous liquid preparation is from about 7 to about 7.5. 21. The stable aqueous liquid preparation of claim 11; wherein the stable aqueous liquid preparation consists of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) water; (f) disodium edetate; (g) sodium sulfite; and (h) a pH adjuster; wherein said liquid preparation is formulated for ophthalmic administration; and wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.04 w/v % to about 0.1 w/v %. 22. The aqueous liquid preparation of claim 1, wherein the aqueous liquid preparation does not include any preservative. 23. The aqueous liquid preparation of claim 6, wherein the aqueous liquid preparation does not include any preservative. 24. The aqueous liquid preparation of claim 11, wherein the aqueous liquid preparation does not include any preservative. 25. The aqueous liquid preparation according to claim 1, optionally further consisting of one or more additives selected from the group consisting of buffers, thickeners, stabilizers, chelating agents, and pH controlling agents.